+

WO2016014992A3 - Compositions pour le traitement, le diagnostic et le pronostic de maladies - Google Patents

Compositions pour le traitement, le diagnostic et le pronostic de maladies Download PDF

Info

Publication number
WO2016014992A3
WO2016014992A3 PCT/US2015/042084 US2015042084W WO2016014992A3 WO 2016014992 A3 WO2016014992 A3 WO 2016014992A3 US 2015042084 W US2015042084 W US 2015042084W WO 2016014992 A3 WO2016014992 A3 WO 2016014992A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
treatment
prognosis
diseases
diagnosis
Prior art date
Application number
PCT/US2015/042084
Other languages
English (en)
Other versions
WO2016014992A2 (fr
Inventor
Jenny L. PERSSON
Heather H. JOHNSON
Original Assignee
Everest Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Everest Biosciences, Inc. filed Critical Everest Biosciences, Inc.
Publication of WO2016014992A2 publication Critical patent/WO2016014992A2/fr
Publication of WO2016014992A3 publication Critical patent/WO2016014992A3/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/010681-Phosphatidylinositol-4-phosphate 5-kinase (2.7.1.68)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne de nouvelles compositions utiles sur le plan pharmaceutique, qui peuvent être utiles dans le traitement de maladies telles que le cancer. L'invention concerne également l'utilisation de ces compositions pour le diagnostic et le pronostic de maladies, la sélection de traitement et la surveillance de la progression d'une maladie.
PCT/US2015/042084 2014-07-24 2015-07-24 Compositions pour le traitement, le diagnostic et le pronostic de maladies WO2016014992A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462028783P 2014-07-24 2014-07-24
US62/028,783 2014-07-24

Publications (2)

Publication Number Publication Date
WO2016014992A2 WO2016014992A2 (fr) 2016-01-28
WO2016014992A3 true WO2016014992A3 (fr) 2016-03-17

Family

ID=55163985

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/042084 WO2016014992A2 (fr) 2014-07-24 2015-07-24 Compositions pour le traitement, le diagnostic et le pronostic de maladies

Country Status (1)

Country Link
WO (1) WO2016014992A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106544361A (zh) * 2016-12-02 2017-03-29 新乡医学院 哺乳动物细胞表达载体、表达系统、制备方法和应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3635952B1 (fr) 2017-06-05 2024-07-03 Immersive Robotics Pty Ltd Compression d'un flux de contenu numérique

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114400A1 (en) * 2001-12-06 2003-06-19 Isis Pharmaceuticals Inc. Antisense modulation of phosphatidylinositol-4-phosphate 5-kinase, Ialpha expression

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114400A1 (en) * 2001-12-06 2003-06-19 Isis Pharmaceuticals Inc. Antisense modulation of phosphatidylinositol-4-phosphate 5-kinase, Ialpha expression

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LI ET AL.: "The ATM Inhibitor KU-55933 Suppresses Cell Proliferation and Induces Apoptosis by Blocking Akt In Cancer Cells with Overactivated Akt.", MOL CANCER THER, vol. 9, no. 1, January 2010 (2010-01-01), pages 113 - 125 *
MUSCOLINI ET AL.: "Phosphatidylinositol 4-Phosphate 5-Kinase alpha Activation Critically Contributes to CD 28-Dependent Signaling Responses.", THE JOURNAL OF IMMUNOLOGY, vol. 190, no. 10, 15 May 2013 (2013-05-15), pages 5279 - 5286 *
VAN DEN BOUT ET AL.: "PIP5K-driven Ptdlns(4,5)P2 synthesis: regulation and cellular function.", J CELL SCI, vol. 122, no. 21, 1 November 2009 (2009-11-01), pages 3837 - 3850 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106544361A (zh) * 2016-12-02 2017-03-29 新乡医学院 哺乳动物细胞表达载体、表达系统、制备方法和应用

Also Published As

Publication number Publication date
WO2016014992A2 (fr) 2016-01-28

Similar Documents

Publication Publication Date Title
IL264049A (en) Compounds, preparations and methods for treating the disease
WO2017030823A3 (fr) Anticorps anti-tigit
EP3448875A4 (fr) Compositions pour le traitement de maladies
EP3448987A4 (fr) Compositions pour le traitement de maladies
EP3675859A4 (fr) Composés, compositions et méthodes pour le traitement d'une maladie
IL264156A (en) Compounds, preparations and methods for treating the disease
MX2022001105A (es) Anticuerpos anti tigit.
WO2016100985A3 (fr) Récepteurs antigéniques chimériques et leurs procédés d'utilisation
EP3177732A4 (fr) Compositions et procédés pour le traitement de maladies et états pathologiques ophthalmiques
WO2015148863A3 (fr) Méthodes liées à crispr/cas et compositions pour le traitement de la drépanocytose
WO2014145490A3 (fr) Sélection, production, traitement et utilisation de cannabis spécialisé
WO2016098079A3 (fr) Compositions et méthodes associées à des anticorps ciblant bmp6
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
EP3182989A4 (fr) Méthodes et compositions destinées à prévenir et à traiter une maladie
WO2015149034A3 (fr) Fusions de gènes et variants de gènes associés au cancer
CN106659716A8 (zh) 阿吡莫德组合物及其使用方法
WO2015123449A3 (fr) Compositions et procédés d'utilisation d'inhibiteurs de micro-arn
WO2016106343A8 (fr) Organismes probiotiques pour le diagnostic, la surveillance et le traitement de la maladie intestinale inflammatoire
WO2015120372A3 (fr) Compositions et méthodes d'inhibition de ezh2 pour traiter des maladies cardiovasculaires
WO2015179835A3 (fr) Biomarqueurs mit et leurs méthodes d'utilisation
EP3149192A4 (fr) Procédés et compositions permettant d'utiliser l'élastase neutrophile et la protéinase 3 en tant que biomarqueurs de diagnostic
EP3218481A4 (fr) Biomarqueurs utiles dans le traitement de sujets souffrant de maladies de l'oeil
EP3137907A4 (fr) Procédés et compositions pour le diagnostic et le traitement de la maladie de kawasaki
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
WO2016094374A8 (fr) Compositions et méthodes de traitement de l'ataxie de friedreich

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15824903

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15824903

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载